Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Low dose naltrexone Stories

2011-07-12 22:35:33

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that a low dose of the opioid antagonist naltrexone (LDN) has an extraordinarily potent antitumor effect on human ovarian cancer in tissue culture and xenografts established in nude mice. When LDN is combined with chemotherapy, there is an additive inhibitory action on tumorigenesis. This discovery, reported in the July 2011 issue of Experimental Biology and Medicine, provides new...

2009-08-25 10:49:00

CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases. The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, randomized...

2009-04-29 12:47:00

Aurora St. Luke's Team Sees Lives Changed for the Better with Plasma Exchange. MILWAUKEE, April 29 /PRNewswire/ -- Researchers at Aurora St. Luke's Medical Center in Milwaukee report that plasma exchange therapy or PLEX dramatically improves the health of multiple sclerosis patients who fail to respond to conventional therapies. (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b) "There is no other treatment that brings about such a reversal in multiple sclerosis," says...

2009-04-23 13:45:47

An inexpensive drug that has been used for years to treat opioid addiction may be the key to relieving pain for millions of fibromyalgia sufferers. Fibromyalgia is a disorder that affects an estimated 4 percent of the population, yet there is no well-established and objective blood test to confirm its diagnosis. Sufferers report experiencing chronic widespread pain, debilitating fatigue, sleep disturbance and joint disorders. A small pilot study at Stanford University tested the effect of a...

2009-03-03 10:36:40

Multiple sclerosis patients may benefit from the drug fampridine. In a new study conducted in centers in the U.S. and Canada, those who received the drug were able to walk faster on standard tests than those who received a placebo for comparison purposes. Leg strength improved more significantly in people taking the active drug as well. The findings held true across a range of MS disease course types. "Treatment with fampridine produces clinically meaningful improvement in walking ability in...

2008-10-07 12:00:19

By JULIA HORTON SCOTTISH scientists claim to have developed a "breakthrough" test that could lead to new medication for thousands of multiple sclerosis patients whose condition is currently untreatable. Researchers at life sciences company Glasgow Health Solutions (GHS) revealed yesterday they have devised a blood test that detects levels of nitrotyrosine, a "bio marker" whose presence indicates chemical activity hat causes the nerve-cell damage that results in MS. Early detection...

2008-10-06 09:00:57

PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today presented data showing the investigational drug, Contrave(R) (naltrexone SR / bupropion SR), successfully achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC) in two Phase 1 clinical trials. In addition, preliminary analysis of blinded data from nearly 4,000 patients...

2008-10-01 09:00:49

Aeolus Pharmaceuticals has initiated a follow-on Phase I open label compassionate use multiple dose study of AEOL 10150 in a patient diagnosed with progressive and debilitating amyotrophic lateral sclerosis, also referred to as ALS or Lou Gehrig's disease. The study is being conducted at University of California, Los Angeles by Martina Wiedau-Pazos and is designed to evaluate the safety and efficacy of AEOL 10150 in an ALS patient over an extended period of time. The patient will receive a...

2006-02-20 14:15:00

NEW YORK (Reuters Health) - An injectable, sustained-release formulation of naltrexone is a safe and effective treatment for patients who are addicted to opioid drugs, such as heroin, new research suggests. Naltrexone in oral form is very effective in preventing and reversing the effects of opioid drugs. However, it has not been particularly useful because patients often stop taking it, according to the report in the Archives of General Psychiatry. The development of a longer lasting...